Johnson & Johnson (JNJ) stock
Johnson & Johnson (JNJ) trades on NYSE and is classified in the Healthcare sector. Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States. This page tracks JNJ using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$271.04
Volume
6,013,143
52-week range
$184.66 – $281.07
Market cap
$652.48B
Source: Polygon (snapshot) · Verified Oct 29, 2026, 5:44 PM EDT
Performance
1D
+1.83%
1W
+2.84%
1M
+2.85%
1Y
+47.48%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Reported financials
Verified · 8 days agoRevenue (TTM)
Reported Q3'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q3'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q3'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q3'26 · Polygon (company financials)
Gross margin
Reported Q3'26 · Polygon (company financials)
Operating margin
Reported Q3'26 · Polygon (company financials)
Net margin
Reported Q3'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q3'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q3'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q3'26 · Verified Oct 20, 2026, 8:00 PM EDT
Valuation
P/E (trailing)
Reported Q3'26 · Ticker-Terminal (last verified price ÷ TTM diluted EPS)
P/E (forward, est.)
Ticker-Terminal (last verified price ÷ annualised consensus EPS estimate)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Earnings
Verified · 8 days agoNext earnings date
Jan 25, 2027
Source: Finnhub earnings calendar
Latest reported quarter
Q3'26
Revenue $25.40B · Diluted EPS 0.09
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-09-30 | 2.59 | 2.56 | +1.0% |
| 2026-06-30 | 2.90 | 2.87 | +0.9% |
| 2026-03-31 | 2.70 | 2.69 | +0.3% |
| 2025-12-31 | 2.46 | 2.46 | -0.1% |
Ticker-Terminal analysis of JNJ
Earnings-power range
Bear $64.30 · Base $80.37 · Bull $96.44 — Significantly Overvalued versus the last verified price.
Bull case
Sustained growth and margin strength support roughly $96.44.
- Applies a 18× earnings multiple to trailing diluted EPS of 4.50, plus a 20% upside band.
- Latest reported revenue growth: 5.9% year over year.
- Operating margin could not be verified.
Base case
Current reported earnings power maps to roughly $80.37 (significantly overvalued versus the last verified price).
- Earnings-power estimate: trailing diluted EPS × a growth-adjusted 18× multiple.
- Implied difference versus the last verified price: -70.9%.
- Trailing operating cash flow: $26.16B.
Bear case
Multiple compression or slowing growth maps to roughly $64.30.
- Applies a 20% downside band to the earnings-power estimate.
- Latest reported EPS growth: -95.8% year over year.
- Downside from the last verified price in this scenario: -76.7%.
Calculated from verified reported financials and the last verified price (data verified Oct 29, 2026, 5:44 PM EDT). Analytical model output, not a price target or investment advice.
Analyst consensus
UnavailableRating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
30
Source: finnhub
Recent JNJ news
Verified · 2 hours ago- Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis?
Yahoo Finance · Oct 29, 2026
- Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings
Seeking Alpha · Oct 28, 2026
- Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
Yahoo Finance · Oct 29, 2026
- Johnson & Johnson Plans To Hold Enterprise Business Review On Dec. 8
Benzinga · Oct 27, 2026
- Johnson & Johnson (JNJ) Stock Trades At A Discount Following Its 97% Run
Yahoo Finance · Oct 27, 2026
- 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
Yahoo Finance · Oct 27, 2026
Data confidence: Partial confidence
Some data is delayed, stale or unavailable. Everything shown is still verified.
- Market data is delayed.
- 1 financial metric unavailable.
What is affected
- Market dataDelayed · 38 minutes ago· Polygon (snapshot)
Still fully reliable
Company profile and business overview · Reported financial statements · Earnings history · Ticker-Terminal analysis
JNJ in its sector
Run full AI research on JNJ
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
JNJ questions, answered
What does Johnson & Johnson do?
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Where is JNJ listed?
Johnson & Johnson trades under the ticker JNJ on NYSE.
What is the JNJ stock price today?
JNJ was last verified at $276.00 (1.83% on the day). After hours, last verified Oct 29, 2026, 5:44 PM EDT. Market data may be delayed and is shown with its own timestamp.
Is Johnson & Johnson revenue growing?
Based on the latest reported financials, JNJ revenue changed 5.9% year over year (filed Oct 20, 2026).
When does Johnson & Johnson report earnings next?
The next confirmed JNJ earnings date is Jan 25, 2027, per Finnhub earnings calendar. Dates can be revised by the company.
What did Johnson & Johnson report in its latest quarter?
For Q3'26, JNJ reported revenue of $25.40B and diluted EPS of 0.09.
What is Ticker-Terminal's JNJ growth score?
Ticker-Terminal scores JNJ at 34/100 (F) from verified growth, profitability, financial strength and valuation inputs. It is an analytical model based on available verified data, not a guarantee of future performance.
How can I run deeper AI research on JNJ?
Create a free Ticker-Terminal account to run a full AI research report on JNJ — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Learn how to read this
Free guide series
Get the “how to research a stock” checklist
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
- The 7-step “how to research a stock” checklist, sent immediately
- The next recommended guide in the series, two days later
- Occasional new guides only — no daily market noise, unsubscribe in one click
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from JNJ's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 29, 2026, 6:22 PM EDT.